Abstract: A method for continuously preparing nano zinc oxide using carbon dioxide. The method includes: step 1, determining experimental materials and experimental instruments; step 2, preparing a raw material and processing the raw material; step 3, oxidizing the preprocessed emulsified zinc slurry; step 4, carbonizing the zinc-free emulsified zinc slurry; step 5, filtering and washing; and step 6, drying and calcining. By using carbon dioxide as a transformation precipitant and using the carbonization method to prepare industrial by-products such as zinc slurry into alkaline zinc carbonate, the nano zinc oxide is obtained through liquid removal, impurity removal, drying, and calcination. Compared with traditional nano zinc oxide preparation methods, the method has a simple and green process flow, a wide source of raw materials, and can prepare nano zinc oxide products with different purities and particle sizes.

Abstract: A method for continuously preparing nano zinc oxide using carbon dioxide. The method includes: step 1, determining experimental materials and experimental instruments; step 2, preparing a raw material and processing the raw material; step 3, oxidizing the preprocessed emulsified zinc slurry; step 4, carbonizing the zinc-free emulsified zinc slurry; step 5, filtering and washing; and step 6, drying and calcining By using carbon dioxide as a transformation precipitant and using the carbonization method to prepare industrial by-products such as zinc slurry into alkaline zinc carbonate, the nano zinc oxide is obtained through liquid removal, impurity removal, drying, and calcination. Compared with traditional nano zinc oxide preparation methods, the method has a simple and green process flow, a wide source of raw materials, and can prepare nano zinc oxide products with different purities and particle sizes.

Abstract: Bifunctional chimeric heterocyclic compounds of formula (I) is effective for targeted degradation of androgen receptors and use thereof. The compound of formula (I) also has an isotopic compound, an optical isomer, a tautomer, pharmacologically acceptable salt, a prodrug thereof, or a solvate. In formula (I), ARB is an androgen receptor recognition/binding part, L is a link part, and U is a ubiquitin protease recognition/binding part; and the three parts are connected by means of chemical bonds. The compound can perform targeted degradation on androgen receptors in prostate cancer cells, and suppress proliferation of the prostate cancer cells, and also show good metabolic stability and pharmacokinetic properties. The compound has good application prospect in preparation of targeted chimeras for protein degradation of androgen receptors and in the preparation of drugs for treating related diseases regulated by the androgen receptors.

Abstract: An aromatic amine androgen receptor (AR) and BET targeting protein degradation chimera compound is represented by formula I. Experimental results show that the compound can target and degrade both AR and BRD4, and down-regulate the expression of AR and BRD4 proteins; the compound can inhibit the proliferation of a variety of prostate cancer cells; the compound can inhibit the proliferation of a prostate cancer cell line LNCaP/AR, which overexpresses the AR, and can achieve a good inhibition effect on a prostate cancer cell line 22RV1, which is resistant to a marketed prostate cancer drug (enzalutamide). The compound also shows good metabolic stability, and has a good application prospect in the preparation of an AR and/or BET protein degradation targeting chimera, and a drug for the treatment of related diseases regulated by the AR and BET.

Abstract: The compound shown in formula I has dual inhibitory effects on AR and BRD4. The compound is not only capable of inhibiting the proliferation of androgen receptor AR multi-expressed prostate cancer cell line LNCAP/AR, but also shows good inhibitory effects on prostate cancer lines VCaP and RRRV1, which are resistant to prostate cancer drugs (enzalutamide) on the market. The compound is also capable of being used for preparing proteolysis-targeting chimeras (PROTACs) for inducing the degradation of AR/BRD4 dual targets, and has good prospects for application in the preparation of drugs for the treatment of AR and BRD4-related diseases.

Abstract: A compound represented by formula (I), or a stereochemical isomer thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, can inhibit the activity of histone acetylase p300 and inhibit the proliferation activity of a variety of tumor cells.

Abstract: The compound of formula (I) has a good inhibitory effect on the proliferation of human prostate cancer cells CWR22RV1 and breast cancer cells; and combined use of the compound with an androgen receptor inhibitor HC-1119 significantly enhances the inhibitory effect on prostate cancer cells, and the inhibitory effect increases with increased concentration. The compound of formula (I) can not only be used independently to prepare an antineoplastic agent but can also be used in combination with other agents having antineoplastic effects, such as an androgen receptor inhibitor, or other targeting drugs etc., to prepare an antineoplastic agent having stronger therapeutic effects, especially an agent for treating prostate cancer and breast cancer.